Autonomic Neuropathy

  • Thomas Mandl
  • Lennart Jacobsson


Autonomic dysfunction (AD) is a feature of many different chronic diseases such as type I and II diabetes, rheumatoid arthritis, systemic lupus erythematosus, scleroderma, and inflammatory bowel disease. Patients with primary Sjögren’s syndrome (pSS) may also show various symptoms of impaired autonomic nervous function such as orthostatic intolerance [1]. The use of autonomic reflex tests (ARTs) in pSS has demonstrated evidence of parasympathetic and sympathetic dysfunction [2–6].


Heart Rate Variability Autonomic Nervous System Autonomic Dysfunction Exocrine Gland Orthostatic Intolerance 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Sakakibara R, Hirano S, Asahina M, et al. Primary Sjögren’s syndrome presenting with generalized autonomic failure. Eur J Neurol. 2004;11:635–8.PubMedCrossRefGoogle Scholar
  2. 2.
    Mandl T, Wollmer P, Manthorpe R, et al. Autonomic and orthostatic dysfunction in primary Sjögren’s syndrome. J Rheumatol. 2007;34:1869–74.PubMedGoogle Scholar
  3. 3.
    Andonopoulos AP, Christodoulou J, Ballas C, et al. Autonomic cardiovascular neuropathy in Sjogren’s syndrome. A controlled study. J Rheumatol. 1998;25:2385–8.PubMedGoogle Scholar
  4. 4.
    Barendregt PJ, van den Meiracker AH, Markusse HM, et al. Parasympathetic failure does not contribute to ocular dryness in primary Sjogren’s syndrome. Ann Rheum Dis. 1999;58:746–50.PubMedCrossRefGoogle Scholar
  5. 5.
    Kovacs L, Paprika D, Takacs R, et al. Cardiovascular autonomic dysfunction in primary Sjogren’s syndrome. Rheumatology. 2004;43:95–9.PubMedCrossRefGoogle Scholar
  6. 6.
    Barendregt PJ, Tulen JH, van den Meiracker AH, et al. Spectral analysis of heart rate and blood pressure variability in primary Sjogren’s syndrome. Ann Rheum Dis. 2002;61:232–6.PubMedCrossRefGoogle Scholar
  7. 7.
    Niemela RK, Hakala M, Huikuri HV, et al. Comprehensive study of autonomic function in a population with primary Sjogren’s syndrome. No evidence of autonomic involvement. J Rheumatol. 2003;30:74–9.PubMedGoogle Scholar
  8. 8.
    Tumiati B, Perazzoli F, Negro A, et al. Heart rate variability in patients with Sjogren’s syndrome. Clin Rheumatol. 2000;19:477–80.PubMedCrossRefGoogle Scholar
  9. 9.
    Cai FZ, Lester S, Lu T, et al. Mild autonomic dysfunction in primary Sjögren’s syndrome: a controlled study. Arthritis Res Ther. 2008;10:R31.PubMedGoogle Scholar
  10. 10.
    Mandl T, Jacobsson L, Lilja B, Sundkvist G, Manthorpe R. Disturbances of autonomic nervous function in primary Sjögren’s syndrome. Scand J Rheumatol. 1997;26:401–6.PubMedCrossRefGoogle Scholar
  11. 11.
    Niemela RK, Pikkujamsa SM, Hakala M, Huikuri HV, Airaksinen KE. No signs of autonomic nervous system dysfunction in primary Sjorgen’s syndrome evaluated by 24 hour heart rate variability. J Rheumatol. 2000;27:2605–10.PubMedGoogle Scholar
  12. 12.
    Kovacs L, Torok T, Bari F, et al. Impaired microvascular response to cholinergic stimuli in primary Sjogren’s syndrome. Ann Rheum Dis. 2000;59:48–53.PubMedCrossRefGoogle Scholar
  13. 13.
    Mandl T, Bornmyr SV, Castenfors J, Jacobsson LT, Manthorpe R, Wollmer P. Sympathetic dysfunction in patients with primary Sjögren’s syndrome. J Rheumatol. 2001;28:296–301.PubMedGoogle Scholar
  14. 14.
    Mandl T, Hammar O, Theander E, Wollmer P, Ohlsson B. Autonomic nervous dysfunction development in patients with primary Sjögren’s syndrome – a follow-up study. Rheumatology. 2010;49(6):1101–6.PubMedCrossRefGoogle Scholar
  15. 15.
    Mandl T, Granberg V, Apelqvist J, et al. Autonomic nervous symptoms in primary Sjogren’s syndrome. Rheumatology. 2008;47:914–9.PubMedCrossRefGoogle Scholar
  16. 16.
    Humphreys-Beher MG, Brayer J, Yamachika S, et al. An alternative perspective to the immune response in autoimmune exocrinopathy: induction of functional quiescence rather than destructive autoaggression. Scand J Immunol. 1999;49:7–10.PubMedCrossRefGoogle Scholar
  17. 17.
    Jonsson R, Kroneld U, Tarkowski A. Histological and functional features of salivary glands in rheumatic patients with oral sicca symptoms. Scand J Rheumatol. 1988;17:387–91.PubMedCrossRefGoogle Scholar
  18. 18.
    Dawson LJ, Fox PC, Smith PM. Sjögren’s syndrome – the non-apoptotic model of glandular hypofunction. Rheumatology. 2006;45:792–8.PubMedCrossRefGoogle Scholar
  19. 19.
    Waterman SA, Gordon TP, Rischmueller M. Inhibitory effects of muscarinic receptor autoantibodies on parasympathetic neurotransmission in Sjogren’s syndrome. Arthritis Rheum. 2000;43:1647–54.PubMedCrossRefGoogle Scholar
  20. 20.
    Gordon TP, Bolstad AI, Rischmueller M, et al. Autoantibodies in primary Sjogren’s syndrome: new insights into mechanisms of autoantibody diversification and disease pathogenesis. Autoimmunity. 2001;34:123–32.PubMedCrossRefGoogle Scholar
  21. 21.
    Dawson L, Tobin A, Smith P, et al. Antimuscarinic antibodies in Sjogren’s syndrome: where are we, and where are we going? Arthritis Rheum. 2005;52:2984–95.PubMedCrossRefGoogle Scholar
  22. 22.
    Mori K, Iijima M, Koike H, et al. The wide spectrum of clinical manifestations in SS associated neuropathy. Brain. 2005;128:2518–34.PubMedCrossRefGoogle Scholar
  23. 23.
    Fox RI, Stern M. Sjogren’s syndrome: mechanisms of pathogenesis involve interaction of immune and neurosecretory systems. Scand J Rheumatol. 2002;116:3–13.Google Scholar
  24. 24.
    Zoukhri D, Hodges RR, Byon D, et al. Role of proinflammatory cytokines in the impaired lacrimation associated with autoimmune xerophthalmia. Invest Ophthalmol Vis Sci. 2002;43:1429–36.PubMedGoogle Scholar
  25. 25.
    Low PA. Composite autonomic scoring scale for laboratory quantification of generalized ­autonomic failure. Mayo Clin Proc. 1993;68:748–52.PubMedGoogle Scholar
  26. 26.
    Mandl T. Autonomic dysfunction in primary Sjögren’s syndrome. Thesis. Lund University; 2008.Google Scholar
  27. 27.
    Waterschoot MP, Guerit JM, Lambert M, et al. Bilateral tonic pupils and polyneuropathy in Sjögren’s syndrome: a common pathophysiological mechanism? Eur Neurol. 1991;31:114–6.PubMedCrossRefGoogle Scholar
  28. 28.
    Theander E, Manthorpe R, Jacobsson LT. Mortality and causes of death in primary Sjogren’s syndrome: a prospective cohort study. Arthritis Rheum. 2004;50:1262–9.PubMedCrossRefGoogle Scholar
  29. 29.
    Borovikova LV, Ivanova S, Zhang M, et al. Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin. Nature. 2000;405:458–62.PubMedCrossRefGoogle Scholar
  30. 30.
    Manthorpe R, Benoni C, Jacobsson L, et al. Lower frequency of focal lip sialadenitis (focus score) in smoking patients. Can tobacco diminish the salivary gland involvement as judged by histological examination and anti-SSA/Ro and anti-SSB/La antibodies in Sjogren’s syndrome? Ann Rheum Dis. 2000;59:54–60.PubMedCrossRefGoogle Scholar
  31. 31.
    Reina S, Orman B, Anaya JM, et al. Cholinoreceptor autoantibodies in Sjögren’s syndrome. J Dent Res. 2007;86:832–6.PubMedCrossRefGoogle Scholar
  32. 32.
    Konttinen YT, Sorsa T, Hukkanen M, et al. Topology of innervation of labial salivary glands by protein gene product 9.5 and synaptophysin immunoreactive nerves in patients with Sjogren’s syndrome. J Rheumatol. 1992;19:30–7.PubMedGoogle Scholar
  33. 33.
    Zoukhri D, Kublin CL. Impaired neurotransmitter release from lacrimal and salivary gland nerves of a murine model of Sjögren’s syndrome. Invest Ophthalmol Vis Sci. 2001;42:925–32.PubMedGoogle Scholar
  34. 34.
    Haddad EB, Rousell J, Lindsay MA, et al. Synergy between tumor necrosis factor alpha and interleukin 1 beta in inducing transcriptional down-regulation of muscarinic M2 receptor gene expression. Involvement of protein kinase A and ceramide pathways. J Biol Chem. 1996;271:32586–92.PubMedCrossRefGoogle Scholar
  35. 35.
    Dawson LJ, Caulfield VL, Stanbury JB, et al. Hydroxychloroquine therapy in patients with primary Sjögren’s syndrome may improve salivary gland hypofunction by inhibition of glandular cholinesterase. Rheumatology. 2005;44:449–55.PubMedCrossRefGoogle Scholar
  36. 36.
    Bacman S, Sterin-Borda L, Camusso JJ, et al. Circulating antibodies against rat parotid gland M3 muscarinic receptors in primary Sjogren’s syndrome. Clin Exp Immunol. 1996;104:454–9.PubMedCrossRefGoogle Scholar
  37. 37.
    Gao J, Cha S, Jonsson R, Opalko J, et al. Detection of anti-type 3 muscarinic acetylcholine receptor autoantibodies in the sera of Sjogren’s syndrome patients by use of a transfected cell line assay. Arthritis Rheum. 2004;50:2615–21.PubMedCrossRefGoogle Scholar
  38. 38.
    Kovacs L, Marczinovits I, Gyorgy A, et al. Clinical associations of autoantibodies to human muscarinic acetylcholine receptor 3(213–228) in primary Sjogren’s syndrome. Rheumatology. 2005;44:1021–5.PubMedCrossRefGoogle Scholar
  39. 39.
    Cavill D, Waterman SA, Gordon TP. Antiidiotypic antibodies neutralize autoantibodies that inhibit cholinergic neurotransmission. Arthritis Rheum. 2003;48:3597–602.PubMedCrossRefGoogle Scholar
  40. 40.
    Dawson LJ, Stanbury J, Venn N, et al. Antimuscarinic antibodies in primary Sjogren’s syndrome reversibly inhibit the mechanism of fluid secretion by human submandibular salivary acinar cells. Arthritis Rheum. 2006;54:1165–73.PubMedCrossRefGoogle Scholar
  41. 41.
    Kovacs L, Papos M, Takacs R, et al. Autonomic nervous system dysfunction involving the gastrointestinal and the urinary tracts in primary Sjogren’s syndrome. Clin Exp Rheumatol. 2003;21:697–703.PubMedGoogle Scholar
  42. 42.
    Wang F, Jackson MW, Maughan V, et al. Passive transfer of Sjogren’s syndrome IgG produces the pathophysiology of overactive bladder. Arthritis Rheum. 2004;50:3637–45.PubMedCrossRefGoogle Scholar
  43. 43.
    Beroukas D, Hiscock J, Gannon BJ, et al. Selective down-regulation of aquaporin-1 in salivary glands in primary Sjogren’s syndrome. Lab Invest. 2002;82:1547–52.PubMedGoogle Scholar
  44. 44.
    Smith AJ, Jackson MW, Wang F, et al. Neutralization of muscarinic receptor autoantibodies by intravenous immunoglobulin in Sjogren syndrome. Hum Immunol. 2005;66:411–6.PubMedCrossRefGoogle Scholar
  45. 45.
    Cavill D, Waterman SA, Gordon TP. Antibodies raised against the second extracellular loop of the human muscarinic M3 receptor mimic functional autoantibodies in Sjogren’s syndrome. Scand J Immunol. 2004;59:261–6.PubMedCrossRefGoogle Scholar
  46. 46.
    Koo NY, Li J, Hwang SM, et al. Functional epitope of muscarinic type 3 receptor which interacts with autoantibodies from Sjögren’s syndrome patients. Rheumatology. 2008;47:828–33.PubMedCrossRefGoogle Scholar
  47. 47.
    Schegg V, Vogel M, Didichenko S, et al. Evidence that anti-muscarinic antibodies in Sjögren’s syndrome recognize both M3R and M1R. Biologicals. 2008;36:213–22.PubMedCrossRefGoogle Scholar
  48. 48.
    Freeman R. Assessment of cardiovascular autonomic function. Clin Neurophysiol. 2006;117:716–30.PubMedCrossRefGoogle Scholar
  49. 49.
    Huikuri HV, Kessler KM, Terracall E, et al. Reproducibility and circadian rhythm of heart rate variability in healthy subjects. Am J Cardiol. 1990;65:391–3.PubMedCrossRefGoogle Scholar
  50. 50.
    Low PA, Denq J-C, Opfer-Gehrking TL, et al. Effect of age and gender on sudomotor and cardiovagal function and blood pressure response to tilt in normal subjects. Muscle Nerve. 1997;20:1561–8.PubMedCrossRefGoogle Scholar
  51. 51.
    Riedel A, Braune S, Kerum G, et al. Quantitative sudomotor axon reflex test (QSART): a new approach for testing distal sites. Muscle Nerve. 1999;22:1257–64.PubMedCrossRefGoogle Scholar
  52. 52.
    Robertson D, Biaggioni I, Burnstock G, Low PA, editors. Primer on the autonomic nervous system. 2nd ed. San Diego: Elsevier Academic press; 2004.Google Scholar
  53. 53.
    Suarez GA, Opfer-Gehrkring TL, Offord KP, et al. The autonomic symptom profile. A new instrument to assess autonomic symptoms. Neurology. 1999;52:523–8.PubMedGoogle Scholar
  54. 54.
    Nikolov NP, Illei GG. Pathogenesis of Sjögren’s syndrome. Curr Opin Rheumatol. 2009;21:465–70.PubMedCrossRefGoogle Scholar
  55. 55.
    Walker J, Gordon T, Lester S, et al. Increased severity of lower urinary tract symptoms and daytime somnolence in primary Sjogren’s syndrome. J Rheumatol. 2003;30:2406–12.PubMedGoogle Scholar
  56. 56.
    Herrick AL. Pathogenesis of Raynaud’s phenomenon. Rheumatology. 2005;44:587–96.PubMedCrossRefGoogle Scholar
  57. 57.
    Kizawa M, Mori K, Iijima M, Koike H, Hattori N, Sobue G. Intravenous immunoglobulin treatment in painful sensory neuropathy without sensory ataxia associated with Sjögren’s syndrome. J Neurol Neurosurg Psychiatry. 2006;77:967–9.PubMedCrossRefGoogle Scholar
  58. 58.
    Dupond JL, Gil H, de Wazieres B. Five-year efficacy of intravenous gammaglobulin to treat dysautonomia in Sjogren’s syndrome. Am J Med. 1999;106:125.PubMedGoogle Scholar
  59. 59.
    Sorajja P, Poirier MK, Bundrick JB, Matteson EL. Autonomic failure and proximal skeletal myopathy in a patient with primary Sjögren syndrome. Mayo Clin Proc. 1999;74:695–7.PubMedCrossRefGoogle Scholar
  60. 60.
    Sève P, Gachon E, Petiot P, Stankovic K, Chahon A, Broussolle C. Successful treatment with rituximab in a patient with mental nerve neuropathy in primary Sjögren’s syndrome. Rheumatol Int. 2007;28:175–7.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag London Limited 2011

Authors and Affiliations

  • Thomas Mandl
    • 1
  • Lennart Jacobsson
    • 1
  1. 1.Department of RheumatologySkane University HospitalMalmöSweden

Personalised recommendations